Failure of acute rejection reversal · kidney transplant recipients: steroid‐resistant rejection episodes
Antibody showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by antibody type) (low certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: steroid‐resistant rejection episodes
Antibody showed no clear difference in recurrent rejection compared with other antibody (stratified by antibody type) (low certainty).
1 finding from 1 review
Graft loss censored for death · kidney transplant recipients: steroid‐resistant rejection episodes
Antibody showed no clear difference in graft loss censored for death compared with other antibody (stratified by antibody type) (low certainty).
1 finding from 1 review
Graft loss or death with a functioning graft · kidney transplant recipients: steroid‐resistant rejection episodes
Antibody showed no clear difference in graft loss or death with a functioning graft compared with other antibody (stratified by antibody type) (low certainty).
1 finding from 1 review
Death · kidney transplant recipients: steroid‐resistant rejection episodes
Antibody showed no clear difference in death compared with other antibody (stratified by antibody type) (low certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: steroid‐resistant rejection episodes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects ‐ Bacterial infection clinical assessment · kidney transplant recipients: steroid‐resistant rejection episodes
It is very uncertain whether antibody changes treatment adverse events: bacterial infection compared with other antibody (stratified by antibody type) (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · heart transplant recipients
Monoclonal antibody showed no clear difference in mortality Mortality at latest compared with polyclonal antibody (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Monoclonal antibody showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Monoclonal antibody showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Monoclonal antibody showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Monoclonal antibody showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with polyclonal antibody (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Monoclonal antibody showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody (low certainty).
1 finding from 1 review
All‐cause mortality · lung transplant recipients
T‐cell antibody induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
1 finding from 1 review
Acute rejection grade II or higher · lung transplant recipients
T‐cell antibody induction showed no clear difference in acute rejection grade II or higher compared with no antibody induction (moderate certainty).
1 finding from 1 review
Infection · lung transplant recipients
T‐cell antibody induction showed no clear difference in infection compared with no antibody induction (moderate certainty).
1 finding from 1 review
Bronchiolitis obliterans syndrome · lung transplant recipients
T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with no antibody induction (moderate certainty).
1 finding from 1 review
All‐cause mortality · lung transplant recipients
Polyclonal T‐cell antibody showed no clear difference in mortality compared with no antibody induction (moderate certainty).
1 finding from 1 review
Acute rejection grade II or higher · lung transplant recipients
Polyclonal T‐cell antibody showed no clear difference in acute rejection grade II or higher compared with no antibody induction (moderate certainty).
1 finding from 1 review
Infection · lung transplant recipients
Polyclonal T‐cell antibody showed no clear difference in infection compared with no antibody induction (moderate certainty).
1 finding from 1 review